Back to resultsThe Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
Primary Purpose
Plaque Psoriasis
Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
TLL018 tablets
Sponsored by
About this trial
This is an interventional treatment trial for Plaque Psoriasis
Eligibility Criteria
Inclusion Criteria: Are between the ages of 18 and 75 years, inclusive, at time of informed consent. Capable of giving informed consent and complying with study procedures. Willing and able to adhere to study restrictions. Laboratory and medical history parameters within the protocol defined ranges. Body mass index (BMI) of 18.0 to 35.0 kg/m2inclusive. Have had a diagnosis of moderate-to-severe PP for at least 6 months prior to Baseline. Participants with moderate-to-severe PP covering ≥10% body surface area (BSA), with a Psoriasis Area and Severity Index (PASI) ≥12 and a static Physician's Global Assessment (PGA) score ≥3 at Baseline. ... Exclusion Criteria: Pregnant or nursing women. History of chronic alcohol or drug abuse within 6 months prior to Screening as determined by the Investigator based on medical history and patient interview Current or recent history of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, neurologic, or psychiatric disease. Current and/or recent history (<30 days prior to Screening and/or <45 days prior to randomization) of a clinically significant viral, bacterial, fungal, parasitic, or mycobacterial infection. Any history of malignancies, except for non-recurrent basal cell skin cancer, squamous cell skin cancer, and cervical cancer in situ that are considered to be cured. Tests positive for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV). Hepatitis B test result positive definition: 1) hepatitis B surface antigen (HBsAg) positive, or 2) Hepatitis B core antibody positive and hepatitis B virus deoxyribonucleic acid positive or beyond the upper limit of normal (ULN) value; positive hepatitis C virus result is defined as having a positive hepatitis C antibody test with a positive confirmatory hepatitis C polymerase chain reaction test. Recent exposure to active tuberculosis (TB). Current evidence of active TB or current evidence of latent TB. Participants with positive TB test (e.g., QuantiFERON) that have been treated for latent TB. Previous or current autoimmune diseases (e.g., RA, systemic lupus erythematosus, IBD, scleroderma, inflammatory myopathy, mixed connective tissue disease overlap syndrome, etc.). Note, psoriatic arthritis patients are allowed. Other types of psoriasis (such as erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, drug-induced psoriasis) ....
Sites / Locations
- CahabaRecruiting
- Moy, Fincher, ChippsRecruiting
- Metropolis DermRecruiting
- Integrative SkinRecruiting
- Skin SurgicalRecruiting
- Life Clinical TrialsRecruiting
- Palm BeachRecruiting
- D&H Doral Research Center LLCRecruiting
- CNS - JacksonvilleRecruiting
- Altus ResearchRecruiting
- AQUA - Riverchase
- Integrated Clinical Trial Services, IncRecruiting
- Lawrence GreenRecruiting
- Metro BostonRecruiting
- Grekin SkinRecruiting
- Revival Research InstituteRecruiting
- Mount SinaiRecruiting
- Remington-Davis, Inc.Recruiting
- DermDoxRecruiting
- CRCCRecruiting
- Derm ResearchRecruiting
- Studies in Dermatology, LLCRecruiting
- Austin Institute for Clinical ResearchRecruiting
- Progressive Clinical Research Group, Inc.Recruiting
- AcclaimRecruiting
- Premier Clinical ResearchRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Placebo Comparator
Arm Label
Cohort 1
Cohort 2
Cohort 3
Cohort 4
Arm Description
TLL018 tables, 10 mg 1piece,BID
TLL018 tables, 20 mg 1piece,BID
TLL018 tables, 40 mg 1piece,BID
placebo, 1piece,BID
Outcomes
Primary Outcome Measures
proportion of participants achieving PASI-75
A patient was a responser if a minimum 75% PASI improvement from Baseline was achieved including measure of the average redness (erythema), thickness (induration), and scaliness (scaling)
In calculating the PASI, severity is determined by dividing the body into four regions: head (h), upper extremities (u), trunk (t), and lower extremities (l).Each of these areas is assessed separately for erythema, induration, and scaling, which are rated on a scale of 0 (none) to 4 (very severe). Extent of psoriatic involvement is graded as follows:
0 = no involvement
= 1% to 9%
= 10% to 29%
= 30% to 49%
= 50% to 69%
= 70% to 89%
= 90% to 100%. PASI = 0.1 (Eh + lh + Sh) Ah + 0.2 (Eu + lu + Su) Au + 0.3 (Et +lt + St) At + 0.4 (El +ll +Sl) Al
Secondary Outcome Measures
Proportion of participants achieving PGA score of 0 or 1
A patient was a responser if PGA score of 0 or 1 condition was reached, as listed: (0 Clear) No signs of psoriasis, but post-inflammatory discoloration may be present; (1 Almost clear): Only minimal plaque elevation, scaling, and erythema.
Proportion of participants achieving PASI-75 (except Week 12)
A patient was a responser if a minimum 75% PASI improvement from Baseline was achieved including measure of the average redness (erythema), thickness (induration), and scaliness (scaling)
In calculating the PASI, severity is determined by dividing the body into four regions: head (h), upper extremities (u), trunk (t), and lower extremities (l).Each of these areas is assessed separately for erythema, induration, and scaling, which are rated on a scale of 0 (none) to 4 (very severe). Extent of psoriatic involvement is graded as follows:
0 = no involvement
= 1% to 9%
= 10% to 29%
= 30% to 49%
= 50% to 69%
= 70% to 89%
= 90% to 100%. PASI = 0.1 (Eh + lh + Sh) Ah + 0.2 (Eu + lu + Su) Au + 0.3 (Et +lt + St) At + 0.4 (El +ll +Sl) Al
Proportion of participants achieving PASI-90
A patient was a responser if a minimum 90% PASI improvement from Baseline was achieved including measure of the average redness (erythema), thickness (induration), and scaliness (scaling)
In calculating the PASI, severity is determined by dividing the body into four regions: head (h), upper extremities (u), trunk (t), and lower extremities (l).Each of these areas is assessed separately for erythema, induration, and scaling, which are rated on a scale of 0 (none) to 4 (very severe). Extent of psoriatic involvement is graded as follows:
0 = no involvement
= 1% to 9%
= 10% to 29%
= 30% to 49%
= 50% to 69%
= 70% to 89%
= 90% to 100%. PASI = 0.1 (Eh + lh + Sh) Ah + 0.2 (Eu + lu + Su) Au + 0.3 (Et +lt + St) At + 0.4 (El +ll +Sl) Al
Full Information
NCT ID
NCT05772520
First Posted
March 6, 2023
Last Updated
September 20, 2023
Sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd
1. Study Identification
Unique Protocol Identification Number
NCT05772520
Brief Title
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
Official Title
A Randomized, Double-blinded, Placebo-controlled, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of TLL018 in Participants With Moderate-to-severe Plaque Psoriasis
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 19, 2023 (Actual)
Primary Completion Date
April 1, 2024 (Anticipated)
Study Completion Date
May 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This is a Phase 2, multicenter, randomized, double-blinded, parallel dose group, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of 3 doses of TLL018 as therapy in 120 participants with moderate-to-severe PP.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Plaque Psoriasis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Cohort 1
Arm Type
Experimental
Arm Description
TLL018 tables, 10 mg 1piece,BID
Arm Title
Cohort 2
Arm Type
Experimental
Arm Description
TLL018 tables, 20 mg 1piece,BID
Arm Title
Cohort 3
Arm Type
Experimental
Arm Description
TLL018 tables, 40 mg 1piece,BID
Arm Title
Cohort 4
Arm Type
Placebo Comparator
Arm Description
placebo, 1piece,BID
Intervention Type
Drug
Intervention Name(s)
TLL018 tablets
Other Intervention Name(s)
TLL018 Placeboes
Intervention Description
oral tablets administered BID for 12weeks
Primary Outcome Measure Information:
Title
proportion of participants achieving PASI-75
Description
A patient was a responser if a minimum 75% PASI improvement from Baseline was achieved including measure of the average redness (erythema), thickness (induration), and scaliness (scaling)
In calculating the PASI, severity is determined by dividing the body into four regions: head (h), upper extremities (u), trunk (t), and lower extremities (l).Each of these areas is assessed separately for erythema, induration, and scaling, which are rated on a scale of 0 (none) to 4 (very severe). Extent of psoriatic involvement is graded as follows:
0 = no involvement
= 1% to 9%
= 10% to 29%
= 30% to 49%
= 50% to 69%
= 70% to 89%
= 90% to 100%. PASI = 0.1 (Eh + lh + Sh) Ah + 0.2 (Eu + lu + Su) Au + 0.3 (Et +lt + St) At + 0.4 (El +ll +Sl) Al
Time Frame
Week12
Secondary Outcome Measure Information:
Title
Proportion of participants achieving PGA score of 0 or 1
Description
A patient was a responser if PGA score of 0 or 1 condition was reached, as listed: (0 Clear) No signs of psoriasis, but post-inflammatory discoloration may be present; (1 Almost clear): Only minimal plaque elevation, scaling, and erythema.
Time Frame
From week 4 to Weeks 12
Title
Proportion of participants achieving PASI-75 (except Week 12)
Description
A patient was a responser if a minimum 75% PASI improvement from Baseline was achieved including measure of the average redness (erythema), thickness (induration), and scaliness (scaling)
In calculating the PASI, severity is determined by dividing the body into four regions: head (h), upper extremities (u), trunk (t), and lower extremities (l).Each of these areas is assessed separately for erythema, induration, and scaling, which are rated on a scale of 0 (none) to 4 (very severe). Extent of psoriatic involvement is graded as follows:
0 = no involvement
= 1% to 9%
= 10% to 29%
= 30% to 49%
= 50% to 69%
= 70% to 89%
= 90% to 100%. PASI = 0.1 (Eh + lh + Sh) Ah + 0.2 (Eu + lu + Su) Au + 0.3 (Et +lt + St) At + 0.4 (El +ll +Sl) Al
Time Frame
From week 4 to Weeks 12(except Week 12)
Title
Proportion of participants achieving PASI-90
Description
A patient was a responser if a minimum 90% PASI improvement from Baseline was achieved including measure of the average redness (erythema), thickness (induration), and scaliness (scaling)
In calculating the PASI, severity is determined by dividing the body into four regions: head (h), upper extremities (u), trunk (t), and lower extremities (l).Each of these areas is assessed separately for erythema, induration, and scaling, which are rated on a scale of 0 (none) to 4 (very severe). Extent of psoriatic involvement is graded as follows:
0 = no involvement
= 1% to 9%
= 10% to 29%
= 30% to 49%
= 50% to 69%
= 70% to 89%
= 90% to 100%. PASI = 0.1 (Eh + lh + Sh) Ah + 0.2 (Eu + lu + Su) Au + 0.3 (Et +lt + St) At + 0.4 (El +ll +Sl) Al
Time Frame
From week 4 to Weeks 12
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Are between the ages of 18 and 75 years, inclusive, at time of informed consent.
Capable of giving informed consent and complying with study procedures.
Willing and able to adhere to study restrictions.
Laboratory and medical history parameters within the protocol defined ranges.
Body mass index (BMI) of 18.0 to 35.0 kg/m2inclusive.
Have had a diagnosis of moderate-to-severe PP for at least 6 months prior to Baseline.
Participants with moderate-to-severe PP covering ≥10% body surface area (BSA), with a Psoriasis Area and Severity Index (PASI) ≥12 and a static Physician's Global Assessment (PGA) score ≥3 at Baseline.
...
Exclusion Criteria:
Pregnant or nursing women.
History of chronic alcohol or drug abuse within 6 months prior to Screening as determined by the Investigator based on medical history and patient interview
Current or recent history of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, neurologic, or psychiatric disease.
Current and/or recent history (<30 days prior to Screening and/or <45 days prior to randomization) of a clinically significant viral, bacterial, fungal, parasitic, or mycobacterial infection.
Any history of malignancies, except for non-recurrent basal cell skin cancer, squamous cell skin cancer, and cervical cancer in situ that are considered to be cured.
Tests positive for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV). Hepatitis B test result positive definition: 1) hepatitis B surface antigen (HBsAg) positive, or 2) Hepatitis B core antibody positive and hepatitis B virus deoxyribonucleic acid positive or beyond the upper limit of normal (ULN) value; positive hepatitis C virus result is defined as having a positive hepatitis C antibody test with a positive confirmatory hepatitis C polymerase chain reaction test.
Recent exposure to active tuberculosis (TB). Current evidence of active TB or current evidence of latent TB. Participants with positive TB test (e.g., QuantiFERON) that have been treated for latent TB.
Previous or current autoimmune diseases (e.g., RA, systemic lupus erythematosus, IBD, scleroderma, inflammatory myopathy, mixed connective tissue disease overlap syndrome, etc.). Note, psoriatic arthritis patients are allowed.
Other types of psoriasis (such as erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, drug-induced psoriasis) ....
Facility Information:
Facility Name
Cahaba
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35244
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Perry
Phone
205-778-1564
Email
jennifer@vialtrials.com
First Name & Middle Initial & Last Name & Degree
Justin Perry
Phone
205-778-1564
Email
jwilliams@cahabaderm.com
First Name & Middle Initial & Last Name & Degree
Vlada Groysman
Facility Name
Moy, Fincher, Chipps
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90210
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ron Moy
Phone
310-274-5372
Email
Ronmoymd@gmail.com
First Name & Middle Initial & Last Name & Degree
Ron Moy
Facility Name
Metropolis Derm
City
Los Angeles
State/Province
California
ZIP/Postal Code
90017
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Felicia Moten
Phone
213-319-3339
Email
trials@metropolisderm.com
First Name & Middle Initial & Last Name & Degree
James Wang
Facility Name
Integrative Skin
City
Sacramento
State/Province
California
ZIP/Postal Code
95815
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elaine Ladmirault
Phone
916-524-1216
Email
elaine@integrativeskinresearch.com
First Name & Middle Initial & Last Name & Degree
Yvonne Nong
Phone
916-524-1216
First Name & Middle Initial & Last Name & Degree
Raja Sivamani
Facility Name
Skin Surgical
City
San Diego
State/Province
California
ZIP/Postal Code
92117
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah Mohsen
Phone
858-292-5101
Ext
110
Email
smohsen@skinsurgerymed.com
First Name & Middle Initial & Last Name & Degree
Anne Truitt
Facility Name
Life Clinical Trials
City
Coral Springs
State/Province
Florida
ZIP/Postal Code
33071
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alondra Escoto
Phone
754-777-2714
Email
aescoto@lctresearch.com
First Name & Middle Initial & Last Name & Degree
Ruth Tecier:
Phone
754-777-2714
First Name & Middle Initial & Last Name & Degree
Eli Saleeby
First Name & Middle Initial & Last Name & Degree
Leeor Porges, DO
Facility Name
Palm Beach
City
DeLand
State/Province
Florida
ZIP/Postal Code
33484
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sammy Ayoub
Phone
561-559-1516
Email
sammy@adamplotkin.com
First Name & Middle Initial & Last Name & Degree
Myesha Ponder
Phone
561-559-1516
First Name & Middle Initial & Last Name & Degree
Adam Plotkin
Facility Name
D&H Doral Research Center LLC
City
Doral
State/Province
Florida
ZIP/Postal Code
33122
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marlon Hernandez
Phone
786-698-8508
Email
marlonher@dhtrc.com
First Name & Middle Initial & Last Name & Degree
Carlos Martinez
Phone
786-698-8508
Email
cMartinez@dhdoral.com
First Name & Middle Initial & Last Name & Degree
Anneyd M. Avalos
First Name & Middle Initial & Last Name & Degree
Anna Cury, MD
First Name & Middle Initial & Last Name & Degree
Brent M. Schillinger
Facility Name
CNS - Jacksonville
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32256
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ivy Gabon
Phone
904-281-5757
Email
igabon@cnshealthcare.com
First Name & Middle Initial & Last Name & Degree
Brooke McFall, RN
Phone
904-281-5757
Email
bmcfall@cnshealthcare.com
First Name & Middle Initial & Last Name & Degree
Fadi Raji Chalhoub
First Name & Middle Initial & Last Name & Degree
Susan Angel, APRN
Facility Name
Altus Research
City
Lake Worth
State/Province
Florida
ZIP/Postal Code
33461
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Florinda Francisco
Phone
561-641-0404
Ext
111
Email
ffrancisco@altusresearch.com
First Name & Middle Initial & Last Name & Degree
Jim Goldberg
Phone
561-641-0404
First Name & Middle Initial & Last Name & Degree
Thomas Ross
First Name & Middle Initial & Last Name & Degree
Samuel Lederman, MD
Facility Name
AQUA - Riverchase
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33028
Country
United States
Individual Site Status
Withdrawn
Facility Name
Integrated Clinical Trial Services, Inc
City
Des Moines
State/Province
Iowa
ZIP/Postal Code
50265
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shelby Simpson
Phone
515-229-1413
Email
ssimpson@ictsiowa.com
First Name & Middle Initial & Last Name & Degree
Rachel Thomas
Phone
515-229-1413
Email
rthomas@ictsiowa.com
First Name & Middle Initial & Last Name & Degree
James Coggi
First Name & Middle Initial & Last Name & Degree
Todd Treimer, DO
First Name & Middle Initial & Last Name & Degree
Mary Barkley, ARNP
Facility Name
Lawrence Green
City
Rockville
State/Province
Maryland
ZIP/Postal Code
20850
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Baccouche
Phone
301-610-0663
Ext
110
Email
jessica@aederm.com
First Name & Middle Initial & Last Name & Degree
Clarissa Ng
Phone
301-610-0663
Email
clarissa@aederm.com
First Name & Middle Initial & Last Name & Degree
Lawrence Green
Facility Name
Metro Boston
City
Brighton
State/Province
Massachusetts
ZIP/Postal Code
02135
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stella Schandorf
Phone
781-444-0900
Email
sschandorf@metrobostoncp.com
First Name & Middle Initial & Last Name & Degree
Brendan Ng
Phone
781-444-0900
Email
brendan@metrobostoncp.com
First Name & Middle Initial & Last Name & Degree
Mark Amster
Facility Name
Grekin Skin
City
Warren
State/Province
Michigan
ZIP/Postal Code
48088
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claudia Attala
Phone
586-759-5525
Ext
3
Email
claudia.attala@adcsclinics.com
First Name & Middle Initial & Last Name & Degree
Nick Sharbo
Phone
586-759-5525
Email
nicholas.sharbo@adcsclinics.com
First Name & Middle Initial & Last Name & Degree
Steven Grekin
Facility Name
Revival Research Institute
City
Troy
State/Province
Missouri
ZIP/Postal Code
48084
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yamini Donekal
Phone
248-590-0298
Email
ydonekal@rev-research.com
First Name & Middle Initial & Last Name & Degree
Manali Ambegaonkar
Phone
248-590-0298
Email
mambegaonkar@rev-research.com
First Name & Middle Initial & Last Name & Degree
Ali Moiin
First Name & Middle Initial & Last Name & Degree
Mohammad Zarka, DO
Facility Name
Mount Sinai
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Grace Ulerio
Phone
212-844-8811
Email
grace.ulerio@mssm.edu
First Name & Middle Initial & Last Name & Degree
Vaishnavi Shreedhar
Email
Vaishnavi.shreedhar@mountsinai.org
First Name & Middle Initial & Last Name & Degree
Alice Gottlieb
Facility Name
Remington-Davis, Inc.
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Heather Lee, NP
Phone
614-487-2560
Email
hlee@remdavis.com
Email
Derm@remdavis.com
First Name & Middle Initial & Last Name & Degree
Michelle Chambers
First Name & Middle Initial & Last Name & Degree
Edward Cordasco, DO
Facility Name
DermDox
City
Sugarloaf
State/Province
Pennsylvania
ZIP/Postal Code
18249
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Suzy Keagy
Phone
717-439-6900
Email
suzy.keagy@yahoo.com
First Name & Middle Initial & Last Name & Degree
Angela Lucero
Phone
717-439-6900
Email
angela@vial.com
First Name & Middle Initial & Last Name & Degree
Stephen Schleicher
First Name & Middle Initial & Last Name & Degree
Zach Sabaday, PA
Facility Name
CRCC
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29407
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gina Gregory
Phone
854-333-5455
Email
gina.gregory@dermandlaser.com
First Name & Middle Initial & Last Name & Degree
Christina Dickinson
Phone
854-333-5455
Email
christina@dermandlaser.com
First Name & Middle Initial & Last Name & Degree
Todd Schlesinger
Facility Name
Derm Research
City
Austin
State/Province
Texas
ZIP/Postal Code
78759
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeremiah Foretenberry
Phone
512-349-9889
Email
jeremiah@vialtrials.com
First Name & Middle Initial & Last Name & Degree
Candice
Phone
512-349-9889
Email
candice@vialtrials.com
First Name & Middle Initial & Last Name & Degree
David Bushore
Facility Name
Studies in Dermatology, LLC
City
Cypress
State/Province
Texas
ZIP/Postal Code
77433
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lilia Garcia
Phone
281-377-6665
Email
lgarcia@studiesindermatology.com
First Name & Middle Initial & Last Name & Degree
Lauren Campbell
First Name & Middle Initial & Last Name & Degree
Sharon R. Kim, MD
Facility Name
Austin Institute for Clinical Research
City
Pflugerville
State/Province
Texas
ZIP/Postal Code
78660
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alivia Hernandez
Phone
512-279-2545
Ext
774
Email
ahernandez@atxresearch.com
First Name & Middle Initial & Last Name & Degree
C Bousquet
Phone
512-279-2545
Email
cbousquet@atxresearch.com
First Name & Middle Initial & Last Name & Degree
Edward Lain
First Name & Middle Initial & Last Name & Degree
Madeleine Gantz, MD
Facility Name
Progressive Clinical Research Group, Inc.
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78213
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amber Rogers
Phone
210-614-5557
Email
arogers@progclin.com
First Name & Middle Initial & Last Name & Degree
Ryann Magee
Phone
210-614-5557
Email
rmagee@progclin.com
First Name & Middle Initial & Last Name & Degree
Mark Lee
First Name & Middle Initial & Last Name & Degree
Theresia Lee, MD
Facility Name
Acclaim
City
Sugar Land
State/Province
Texas
ZIP/Postal Code
77479
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carina Espinoza
Phone
832-770-6388
Ext
106
Email
research@acclaimderm.com
First Name & Middle Initial & Last Name & Degree
Syed Ali
Facility Name
Premier Clinical Research
City
Spokane
State/Province
Washington
ZIP/Postal Code
99202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anna Dominguez
Phone
509-998-0238
Email
ADominguez@premierclinicalresearch.com
First Name & Middle Initial & Last Name & Degree
Celeste Gray
Phone
509-998-0238
Email
CGray@premierclinicalresearch.com
First Name & Middle Initial & Last Name & Degree
Philip Werschler
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
We'll reach out to this number within 24 hrs